CPO 4

CPO 4 (0.001-0.416 mM) potently inhibits the growth of Enterococcus faecalis p1-2007226001 with an MIC of 0.001 mM, and exhibits varying levels of antibacterial activity against 10 additional tested bacterial strains^[1].
CPO 4 (0.006-0.208 mM; 4 h) exhibits negligible hemolytic activity against red blood cells, with a hemolysis rate below 5% at 0.208 mM after 4 h, and preserves RBC structural integrity at 0.052 mM^[1].
CPO 4 (14 bacterial passages) displays a low propensity for inducing resistance in Enterococcus faecalis p1-2007226001, with stable MIC values over 14 passages^[1].
CPO 4 (0.5×-4×MIC) dose-dependently reduces the metabolic activity of Enterococcus faecalis p1-2007226001, with the greatest reduction at 4×MIC^[1].
CPO 4 (0.5×-4×MIC) dose-dependently induces protein leakage from Enterococcus faecalis p1-2007226001, reaching a maximum leaked protein concentration of 25 μg/mL at 4×MIC^[1].
CPO 4 exhibits favorable drug-likeness and pharmacokinetic properties, with 0 Lipinski violations, a bioavailability score of 0.55, high predicted GI absorption, and no predicted blood-brain barrier permeation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.